|
End-of-day quote
Mexican S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 2,520.00 MXN | +1.82% |
|
+5.52% | +13.40% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
| Market Cap | 184B 3,126B 158B 149B 136B 256B 17,599B 257B 1,756B 682B 8,876B 693B 678B 29,380B | P/E 2026 * |
-45.5x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 201B 3,410B 173B 162B 148B 279B 19,196B 280B 1,915B 744B 9,682B 755B 739B 32,047B | EV / Sales 2026 * |
6.56x | EV / Sales 2027 * | 5.92x |
| Free-Float |
99.88% | Yield 2026 * |
2.22% | Yield 2027 * | 2.28% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +1.82% | ||
| 1 week | +5.52% | ||
| Current month | +9.51% | ||
| 1 month | +10.77% | ||
| 3 months | +8.39% | ||
| 6 months | -3.56% | ||
| Current year | +13.40% |
| 1 week | 2,475 |  | 2,520 |
| 1 month | 2,285.47 | | 2,520 |
| Current year | 2,116 | | 2,618.71 |
| 1 year | 2,025.32 | | 2,618.71 |
| 3 years | 1,046.71 | | 2,618.71 |
| 5 years | 1,046.71 | | 2,618.71 |
| 10 years | 1,046.71 | | 2,618.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 2019-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 2019-10-31 |
Keeley Wettan
CMP | Compliance Officer | - | 2025-12-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 2016-08-18 |
| Director/Board Member | 73 | 2017-12-31 | |
Harish Manwani
BRD | Director/Board Member | 72 | 2018-05-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.82% | +5.52% | - | - | 184B | |
| -3.59% | -2.96% | +71.06% | +114.83% | 1,100B | |
| -1.15% | -0.41% | +51.34% | +62.41% | 658B | |
| -1.09% | +1.54% | +26.67% | +79.22% | 470B | |
| -1.47% | +2.05% | +41.71% | +42.09% | 372B | |
| -0.90% | +1.29% | +25.62% | +41.75% | 304B | |
| -1.94% | +1.53% | +3.05% | +13.24% | 264B | |
| -0.43% | +3.54% | +52.65% | +71.75% | 239B | |
| -0.93% | +2.90% | -16.98% | -52.28% | 213B | |
| -0.46% | +3.24% | +29.73% | +92.67% | 184B | |
| Average | -0.64% | +3.01% | +31.65% | +51.74% | 422.54B | |
| Weighted average by Cap. | -0.61% | +2.21% | +42.86% | +68.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.69B 520B 26.34B 24.71B 22.58B 42.59B 2,928B 42.77B 292B 113B 1,477B 115B 113B 4,888B | 32.7B 554B 28.06B 26.32B 24.05B 45.36B 3,119B 45.56B 311B 121B 1,573B 123B 120B 5,207B |
| Net income | -4.27B -72.44B -3.67B -3.44B -3.14B -5.93B -408B -5.96B -40.69B -15.8B -206B -16.05B -15.7B -681B | 10.28B 174B 8.82B 8.27B 7.56B 14.26B 980B 14.32B 97.8B 37.98B 494B 38.58B 37.74B 1,637B |
| Net Debt | 16.75B 284B 14.37B 13.48B 12.32B 23.23B 1,598B 23.33B 159B 61.9B 806B 62.87B 61.5B 2,667B | 9.12B 155B 7.83B 7.35B 6.71B 12.66B 870B 12.71B 86.85B 33.73B 439B 34.26B 33.51B 1,453B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-26 | MX$2,536.66 | +0.66% | 458 |
| 26-08-25 | MX$2,520.00 | +1.82% | 7 |
| 26-08-24 | MX$2,475.00 | +0.62% | 14 |
| 26-08-19 | MX$2,459.87 | +3.00% | 300 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD * Stock
Select your edition
All financial news and data tailored to specific country editions
